NCT03470311已完成3 期
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Sputum eosinophil percentage
研究概览
简要总结
In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control
详细描述
Benralizumab thus targets 'eosinophil biology', by inhibiting the interleukin (IL-5) receptor signalling, and inducing apoptosis in cells with an IL-5receptor. Hence, for patients who remain 'uncontrolled' on anti-IL-5 therapy (with detectable eosinophil activity and IL5-Rα+ cells in the airways), the investigators believe would benefit from a strategy that not only reduces eosinophil proliferation/recruitment/maturation, but also depletes cells capable of inducing downstream IL-5 signalling.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent Prior to the beginning of the study, patients must be willing and fully capable to provide written informed consent.
- •Diagnosed prednisone-dependent eosinophilic asthma
- •Previous treatment with 100 mg mepolizumab administered subcutaneously Q4W or reslizumab 3 mg/kg IV Q4W for at least 6 months
- •Sputum eosinophils >3%
- •Male or eligible female subjects:
- •To be eligible for entry into the study, females of childbearing potential (premenopausal women who are not permanently sterilized by means of hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) must commit to consistent and correct use of a highly effective method of birth control (true sexual abstinence, a vasectomized sexual partner, Implanon, female tubal occlusion, Intrauterine device (IUD), Depo provera injections, oral contraceptive pills or Nuvaring) for the duration of the trial and for 3 months after the last study drug administration. A serum pregnancy test is required of all females at the initial Baseline Visit (Visit 1). In addition, a urine pregnancy test will be performed for all females prior to enrollment, during each scheduled study visit prior to the injection of investigational product, and during the Follow-up Visit.
- •Male subjects who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of study drug and for 3 months after the last dose of study drug.
排除标准
- •Currently receiving another monoclonal antibody
- •Intolerance, hypersensitivity, insensitivity or neutralizing antibody to Mepolizumab and/or Reslizumab
- •Malignancy within the last 5 years
- •Any co-morbidity that the investigator believes is a contraindication. This includes but is not limited to any respiratory, cardiovascular, gastrointestinal, hematological, neurological, immunological, musculoskeletal, renal, infectious, neoplastic or inflammatory condition that may place the safety of the subject at risk during the duration of the study, influence the results of the study or their interpretation, or prevent the patient from completing the entire duration of the study.
- •Current pregnancy or lactation
- •Current smoker or ex-smoker with a smoking history greater than 20 pack years.
结局指标
主要结局
Sputum eosinophil percentage
时间窗: Visit 1 (Week 2) and Visit 10 (Week 38)
Change in Percentage of sputum eosinophils (%)
次要结局
- Fraction of exhaled nitric oxide (FeNO)(Visit 1 (Week 2) and Visit 10 (Week 38))
- Sputum and blood ILC2 biology(Visit 1 (Week 2) and Visit 10 (Week 38))
- Blood eosinophils(Visit 1 (Week 2) and Visit 10 (Week 38))
- Forced Expired Volume in 1 second (FEV1)(pre and post bronchodilator)(Visit 1 (Week 2) and Visit 10 (Week 38))
- ACQ-5 (Asthma Control Questionnaire)(Visit 1 (Week 2) and Visit 10 (Week 38))
- Number of Exacerbations (defined as: ER visit/hospitalization requiring prednisone burst)(Visit 1 (Week 2) and Visit 10 (Week 38))
- Sputum autoimmune responses(Visit 1 (Week 2) and Visit 10 (Week 38))
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Effect of Benralizumab on Airway Remodeling in AsthmaAsthmaNCT04365205University Hospital, Bordeaux60
已完成
4 期
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory ImagingAsthmaNCT05552508AstraZeneca45
招募中
不适用
Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic AsthmaEosinophilic AsthmaNCT04512521Hannover Medical School40
已完成
4 期
Efficacy of Reslizumab Dose Escalation in Patients With Severe AsthmaEosinophilic AsthmaNCT04710134McMaster University10
尚未招募
2 期
Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT05273359Temple University45